Merck & Co Inc (FRA:6MK)
€ 92.9 -0.2 (-0.21%) Market Cap: 236.96 Bil Enterprise Value: 261.27 Bil PE Ratio: 21.36 PB Ratio: 5.93 GF Score: 78/100

Merck & Co Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 12:30AM GMT
Release Date Price: €108.6 (+1.50%)
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Merck today. From the company, we have Rob Davis, Chairman and CEO as well as Dean Lee, President of Merck Research Labs. So Rob and Dean, Happy New Year. And great speaking of you today. We're going to have a presentation from Rob, and then we're going to move over to a Q&A session from there.

But obviously, it's been quite a year for Merck or quite a few years for Merck. Company's built on its pipeline really nicely. It's been active in a lot of deals. So excited to hear from the progress the company has been making. So with that, turn it over to Rob.

Robert M. Davis
Merck & Co., Inc. - Chairman, President & CEO

Thanks. All right. Great. Happy New Year, everyone. Thanks for having us. Before we get started, I did want to just point out I will be making forward-looking statements, which obviously you can see our statement here and go to our website if you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot